Elligo hits 100-million patient mark with network

By Jenni Spinner

- Last updated on GMT

(Prostock-Studio/iStock via Getty Images Plus)
(Prostock-Studio/iStock via Getty Images Plus)

Related tags Elligo Health Research Patient recruitment Clinical trials Data management Study start-up

Thanks to collaborations with Cerner, amassing of proprietary data and other achievements, the trial solutions firm has hit a significant access milestone.

Elligo Health Research has announced it now has the ability to connect clinical trial teams with access to more than 100m patients. According to the company, the milestone has been made possible via the company’s proprietary data, as well as collaborations with firms such as Cerner, which offers the Learning Health Network of nationwide health systems committed to sharing data in the support of advancing clinical research.

At a virtual press event on Monday, February 1, Elligo Health Research CEO John Potthoff told Outsourcing-Pharma that partnerships with Cerner and other companies helps to broaden the array of solutions and access available to clinical trial professionals.

This gives us access into a much broader, larger population of healthcare providers and patients​,” he remarked. "It also goes to enhance the focus we have on diversity in clinical trials​.”

Potthoff said while technology has enabled clinical trial professionals to address sponsor demands for accelerated timelines in their studies, patient enrollment periods have lengthened, and improved access to potential patient participants can provide a path to shortening the time required for recruitment.

Christy Dueck, PhD (Cerner’s vice president and general manager, real world data and clinical research), told OSP at the press event that the need to increase clinical researchers’ access to a broader patient population can help address persistent challenges like disparities in heathcare—one of the problems the COVID-19 pandemic has helped bring front and center. Collaborations among partners like Cerner and Elligo Health Research can make solutions to such problems a reality, she said.

Cerner is the accelerant; Elligo is the activator​,” she stated.

Elligo’s single-platform technology is intended to enable private-practice physicians to offer research as a care option within their own practices, enabling trials to build upon their patient access.

Elligo, from its inception, has been focused on maximizing access to research as a patient care option​,” Potthoff said. “With over 100m patients in the Elligo network, we’re more able to do that today than ever before, and we’re excited to continue leading the industry in this crucial initiative. Because patients are waiting​.”

Elligo Health Research and Cerner announced their partnership at the end of 2020​. The commercial agreement sought to bring together Cerner’s access to health practices and patients with Elligo’s clinical trial expertise in order to broaden options for patients and providers in less-accessible communities.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more